Greg co-founded Biodesy, Inc., and now serves as CEO. He is an entrepreneurial leader and general manager who specializes in building rapidly growing companies in dynamic markets. His background includes small, medium, and large businesses focused on cutting edge research tools, translational medicine, and medical diagnostics. Greg was most recently the first-ever healthcare Entrepreneur in Residence at GE, where he was responsible for strategic business assessment and planning for novel GE technology. Previously, Greg was Lifecycle Leader, Advanced Staining Assays, at Ventana Medical Systems, a member of the Roche Group, where he led Ventana’s market-leading ~$500M cancer diagnostic assay business. These products, ranging from standard-of-care tests for all major cancers to novel proprietary assays and companion diagnostics, are used to guide treatment for nearly half of all cancer patients worldwide. Greg was also Chief Operating Officer of CELLective Dx, a venture-backed startup developing an innovative platform for analyzing circulating tumor cells, and held general management roles at Affymetrix, the pioneer of DNA microarrays, including VP Molecular Diagnostics and VP DNA Products, where he started and grew the genetics business from zero to ~$100 million in revenue. Greg has also worked in venture capital with Bay City Capital and in management consulting with McKinsey & Company. He is a member of the boards of directors of Outward Bound California and the national Outward Bound Services Group. Greg received his MBA from Stanford University and his AB in molecular biology, summa cum laude, from Princeton University.


Dr. Salafsky is the Founder of Biodesy and the inventor of the SHG technique for detecting biological molecules. He established SHG as a structural technique for proteins and other biomolecules over a decade in Biodesy. Over this period, he also managed the company, raised angel financing, was awarded grants from the NIH and NSF, and obtained the key scientific results that attracted the attention of the venture capital community. During diligence with 5AM Ventures, he was introduced to Greg Yap and they completed the first venture financing of Biodesy together. Prior to founding Biodesy, Dr. Salafsky was a postdoctoral fellow in the Dept. of Chemistry at Columbia University and the Dept. of Physics at Utrecht University in the Netherlands, as well as a guest researcher at the Cavendish Laboratory at the University of Cambridge, UK. During this time, he invented ‘SHG labels’ and the first single-nanocrystal photovoltaic device, a new and highly efficient architecture for photodetectors and solar cells. Dr. Salafsky’s expertise and interests are in the areas of Biophysics, Physical Chemistry, and Device Physics. He received his PhD from Stanford University where he studied the reaction center protein, the marvelous engine at the heart of photosynthesis that converts light into chemical energy, powering all life.